Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27905995 | 0.80 | MEN1 (0.33) | DAOKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL28074920 | 0.79 | DAO (0.36) | DAOCRBNCYP3A4PMP22MAPK1 | |
| SCHEMBL19036625 | 0.77 | DAO (0.35) | DAOCRBNCYP3A4PMP22MAPK1 | |
| SCHEMBL24316295 | 0.75 | MET (0.40) | DAOKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL643987 | 0.73 | PARP1 (0.39) | DAOCYP3A4PMP22MAPK1KMT2A | |
| SCHEMBL19036768 | 0.72 | KMT2A (0.38) | DAOCYP3A4PMP22MAPK1KMT2A | |
| SCHEMBL16248 | 0.71 | MAPK1 (0.47) | DAOCRBNMAPK1ALDH1A1HPGD | |
| SCHEMBL2986044 | 0.70 | DAO (0.46) | DAOCRBNCYP3A4PMP22MAPK1 | |
| SCHEMBL35345 | 0.70 | TDP1 (0.57) | DAOCRBNKMT2AMEN1ALDH1A1 | |
| SCHEMBL4379053 | 0.70 | DAO (0.43) | DAOCRBNCYP3A4PMP22MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024231230-A2 | CIRCULAR NUCLEIC ACIDS AND USES THEREOF FOR SHAPING THE CELLULAR PROTEOME | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN KÖRPERSCHAFT DES ÖFFENTLICHEN RECHTS (DE) | 2024-11-14 | — | — | WO | disclosed |
| EP-4458968-A1 | CIRCULAR NUCLEIC ACIDS AND USES THEREOF FOR SHAPING THE CELLULAR PROTEOME | Justus-Liebig-Universität Gießen (DE) | 2024-11-06 | — | — | EP | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023130021-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED DELIVERY PROPERTIES | PHIO PHARMACEUTICALS CORP. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023015264-A1 | IMMUNOTHERAPY OF CANCER UTILIZING NATURAL KILLER CELLS TREATED WITH CHEMICALLY MODIFIED OLIGONUCLEOTIDES | PHIO PHARMACEUTICALS CORP. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023280156-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2023-01-12 | — | — | WO | disclosed |
| EP-4055167-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY | Phio Pharmaceuticals Corp. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4008785-A1 | CIRCULAR NUCLEIC ACIDS AND USES THEREOF FOR INTERFERING WITH GENOME EXPRESSION AND PROLIFERATION OF CORONAVIRUSES | Justus-Liebig-Universität Gießen (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-3209335-A1 | AGENTS FOR USE IN THE DETECTION OF NUCLEASE ACTIVITY | Hernández Hincapié, Frank J. (ES) | 2017-08-30 | — | — | EP | disclosed |
| EP-3105330-A1 | MiR-21-3p INHIBITORS IN SKIN DISORDERS | Université de Lausanne (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-2057273-A2 | USE OF SUBTILISIN (RNR9) POLYNUCLEOTIDES FOR ACHIEVING A PATHOGEN RESISTANCE IN PLANTS | BASF Plant Science GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| EP-1979484-A1 | USE OF STOMATIN (STM1) POLYNUCLEOTIDES FOR ACHIEVING A PATHOGEN RESISTANCE IN PLANTS | BASF Plant Science GmbH (DE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1948806-A2 | USE OF ARMADILLO REPEAT (ARM1) POLYNUCLEOTIDES FOR OBTAINING PATHOGEN RESISTANCE IN PLANTS | BASF Plant Science GmbH (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008087141-A2 | USE OF SUBTILISIN (RNR9) POLYNUCLEOTIDES FOR ACHIEVING A PATHOGEN RESISTANCE IN PLANTS | BASF PLANT SCIENCE GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-20080120740-A1 | Novel Nucleic Acid Sequences and Their Use in Methods for Achieving a Pathogenic Resistance in Plants | BASF PLANT SCIENCE GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| WO-2007080143-A1 | USE OF STOMATIN (STM1) POLYNUCLEOTIDES FOR ACHIEVING A PATHOGEN RESISTANCE IN PLANTS | BASF PLANT SCIENCE GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007054441-A2 | USE OF ARMADILLO REPEAT (ARM1) POLYNUCLEOTIDES FOR OBTAINING PATHOGEN RESISTANCE IN PLANTS | BASF PLANT SCIENCE GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1747275-A2 | NOVEL NUCLEIC ACID SEQUENCES AND THEIR USE IN METHODS FOR ACHIEVING A PATHOGENIC RESISTANCE IN PLANTS | BASF Plant Science GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005111215-A2 | NOVEL NUCLEIC ACID SEQUENCES AND THEIR USE IN METHODS FOR ACHIEVING A PATHOGENIC RESISTANCE IN PLANTS | BASF PLANT SCIENCE GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20030082678-A1 | Methods and compositions for regulating body weight in bovine species | ELI LILLY AND COMPANY | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | DAO 4160/4885CRBN 50/4885CYP3A4 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.